+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-11-11Number of Pages: 196

Pulmonary Drugs Market (Drug Class - Inhaled Corticosteroids (ICS), Long-Acting Beta2-Agonists (LABA), Antihistamines, Vasodilators, Short-Acting Beta2-Agonists (SABA), Anticholinergics, Combination Drugs, MAbs, Enzymes, Antibiotics, and Antileukotrienes; Application - Asthma & COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension, and Cystic Fibrosis; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, and E-commerce) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024

Global Pulmonary Drugs Market: Snapshot 

The global pulmonary drugs market has been the key area of focus and the most crucial market for the healthcare industry in the last couple of years. However, the market is expected to witness a significant decline over the forecast period with a -6.3% CAGR from 2016 to 2024. The market is anticipated to fall to US$28,082.1 mn from a valuation of US$48,039.7 mn in 2015. Keeping aside the tremendous fall of the global pulmonary drugs market, it has been expected that the market will find growth prospects from the growing number of respiratory diseases and the fact that they are becoming the leading cause of deaths across the globe at present, especially among the aged population. 

According to the Forum of International Respiratory Societies (FIRS), chronic obstructive pulmonary disease affects over 200 million people across the globe and is also one of the leading causes of death globally. On the other, over 235 million people across the globe suffer from asthma. Owing to these alarming statistics, the consumption of pulmonary drugs is likely to gain momentum, thus providing growth opportunities to the market in spite of the negative CAGR. Pulmonary drugs are also being employed for the treatment of conditions such as cystic fibrosis, respiration-related disorders, pulmonary arterial hypertension (PAH), and allergic rhinitis. The launch of many effective and innovative drugs in the global market for pulmonary drugs is also anticipated to have a positive impact on the growth of the market in the coming years. 

pulmonary drugs market

Medical Professionals to Prefer Combination Drugs among All Others 

Based on drug classes, the global market for pulmonary drugs is classified into combination drugs, anticholinergics, short acting beta2-agonists, vasodilators, antihistamines, long-acting beta2-agonists, and inhaled corticosteroids, and others such as antileukotrienes, antibiotics, enzymes, and monoclonal antibodies. Among these, the segment of combination drugs held the leading share of 27.4% in 2015 closely followed by inhaled corticosteroids with a share of 16.7% in the same year in the global pulmonary drugs market. The sales of combination drugs is likely to remain high throughout the forecast period as they are considered to be comparatively safer than the other drugs. Moreover, the advent of triple combination drugs is further projected to propel the growth of the global pulmonary drugs market over the course of the forecast period. 

Advent of Middle-income Classes to Catapult Demand in Asia Pacific 

Based on geography, the global market for pulmonary drugs has been classified into Asia Pacific, North America, Europe, the Middle East and Africa, and Latin America. In 2015, North America led the global pulmonary drugs market with a share of 41% with Europe closely following with a share of 32.4% in the same year. The growing use of pulmonary drugs in these regions can be attributed to the advanced healthcare infrastructure coupled with high awareness regarding treatment of pulmonary diseases. However, the rise of middle-income classes and their growing expenditure on healthcare is expected to lift Asia Pacific as a prominent region in the global market. 

Some of the leading players in the market are Actelion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, AstraZeneca plc, and Sunovion Pharmaceuticals Inc.

1. Preface
     1.1. Report Scope
     1.2. Market Segmentation 
     1.3. Research Highlights

2. Assumptions and Research Methodology
     2.1. Assumptions
     2.2. Acronyms Used
     2.3. Research Methodology

3. Executive Summary

4. Market Overview
     4.1. Drug Class Overview
     4.2. Key Industry Events
     4.3. Market Opportunity Map

5. Market Dynamics
     5.1. Drivers and Restraints Snapshot Analysis
     5.2. Drivers
     5.3. Restraints
     5.4. Opportunity Analysis
     5.5. Opportunities
     5.6. Trends
     5.7. Porter’s Five Forces Analysis 
     5.8. Value Chain Snapshot
     5.9. Pulmonary Drugs Market Outlook

6. Pulmonary Drugs Market Analysis, by Drug Class
     6.1. Key Findings
     6.2. Introduction
     6.3. Global Pulmonary Drugs Market Value Share Analysis, by Drug Class
     6.4. Global Pulmonary Drugs Market Forecast, by Drug Class
             6.4.1. Global Inhaled Corticosteroids (ICS) Market Revenue, US$ Mn, 2014–2024
             6.4.2. Global Long-Acting Beta2-Agonists (LABA) Market Revenue, US$ Mn, 2014–2024
             6.4.3. Global Antihistamines Market Revenue, US$ Mn, 2014–2024
             6.4.4. Global Vasodilators Market Revenue, US$ Mn, 2014–2024
             6.4.5. Global Short-Acting Beta2-Agonists (SABA) Market Revenue, US$ Mn, 2014–2024
             6.4.6. Global Anticholinergics  Market Revenue, US$ Mn, 2014–2024
             6.4.7. Global Combination Drugs Market Revenue, US$ Mn, 2014–2024
             6.4.8. Global Other Pulmonary Drugs Market Revenue, US$ Mn, 2014–2024
     6.5. Global Pulmonary Drugs Market Attractiveness Analysis, by Drug Class
     6.6. Key Trends

7. Pulmonary Drugs Market Analysis, by Application
     7.1. Key Findings
     7.2. Introduction
     7.3. Global Pulmonary Drugs Market Value Share Analysis, By Application, 2016 and 2024
     7.4. Global Pulmonary Drugs Market Size (US$ Mn) Forecast, By Application, 2014–2024
             7.4.1. Global Asthma and COPD Market Revenue, US$ Mn, 2014–2024
             7.4.2. Global Allergic Rhinitis Market Revenue, US$ Mn, 2014–2024
             7.4.3. Global Pulmonary Arterial Hypertension Market Revenue, US$ Mn, 2014–2024
             7.4.4. Global Cystic Fibrosis Market Revenue, US$ Mn, 2014–2024
             7.4.5. Global Other Applications Market Revenue, US$ Mn, 2014–2024
     7.5. Global Pulmonary Drugs Market Attractiveness By Application
     7.6. Key Trends

8. Pulmonary Drugs Market Analysis, by Distribution Channel
     8.1. Key Findings
     8.2. Introduction
     8.3. Global Pulmonary Drugs Market Value Share Analysis, By Distribution Channel, 2016 and 2024     
     8.4. Global Pulmonary Drugs Market Size (US$ Mn) Forecast, By Distribution Channel, 2015–2024
             8.4.1. Global Hospital Pharmacies Market Revenue, US$ Mn, 2014–2024
             8.4.2. Global Retail Pharmacies Market Revenue, US$ Mn, 2014–2024
             8.4.3. Global Drug Stores Market Revenue, US$ Mn, 2014–2024
             8.4.4. Global E-commerce Market Revenue, US$ Mn, 2014–2024
     8.5. Global Pulmonary Drugs Market Attractiveness By Distribution Channel

9. Pulmonary Drugs Market Analysis, By Region
     9.1. Global Scenario
     9.2. Global Pulmonary Drugs Market Value Share Analysis By Region, 2016 and 2024
     9.3. Global Pulmonary Drugs Market Size (US$ Mn) Forecast, By Region, 2016–2024
     9.4. Global Pulmonary Drugs Market Attractiveness Analysis, by Region

10. North America Pulmonary Drugs Market Analysis
     10.1. Key Findings
     10.2. North America Pulmonary Drugs Market Size (US$ Mn) Forecast, 2016–2024
     10.3. North America Market Attractiveness Analysis, by Country
     10.4. North America Market Value Share Analysis, by Product Type, 2016 and 2024
     10.5. North America Pulmonary Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
     10.6. North America Market Value Share Analysis, by Application, 2016 and 2024
     10.7. North America Pulmonary Drugs Market Size (US$ Mn) Forecast, by Application, 2016–2024
     10.8. North America Market Value Share Analysis, by Distribution Channel, 2016 and 2024
     10.9. North America Pulmonary Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
     10.10. North America Market Value Share Analysis, by Country, 2016 and 2024
     10.11. North America Pulmonary Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2024
     10.12. North America Market Attractiveness Analysis, by Drug Class
     10.13. North America Market Attractiveness Analysis, by Application
     10.14. North America Market Attractiveness Analysis, by Distribution Channel

11. Europe Pulmonary Drugs Market Analysis
     11.1. Key Findings
     11.2. Europe Pulmonary Drugs Market Size (US$ Mn) Forecast, 2016–2024
     11.3. Europe Market Attractiveness Analysis, by Country
     11.4. Europe Market Value Share Analysis, by Drug Class, 2016 and 2024
     11.5. Europe Pulmonary Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
     11.6. Europe Market Value Share Analysis, by Application, 2016 and 2024
     11.7. Europe Pulmonary Drugs Market Size (US$ Mn) Forecast, by Application, 2016–2024
     11.8. Europe Market Value Share Analysis, by Distribution Channel, 2016 and 2024
     11.9. Europe Pulmonary Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
     11.10. Europe Market Value Share Analysis, by Country, 2016 and 2024
     11.11. Europe Pulmonary Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2024
     11.12. Europe Market Attractiveness Analysis, by Drug Class
     11.13. Europe Market Attractiveness Analysis, by Application
     11.14. Europe Market Attractiveness Analysis, by Distribution Channel

12. Asia Pacific Pulmonary Drugs Market Analysis
     12.1. Key Findings
     12.2. Asia Pacific Pulmonary Drugs Market Size (US$ Mn) Forecast, 2016–2024
     12.3. Asia Pacific Market Attractiveness Analysis, by Country
     12.4. Asia Pacific Market Value Share Analysis, by Drug Class, 2016 and 2024
     12.5. Asia Pacific Pulmonary Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
     12.6. Asia Pacific Market Value Share Analysis, by Application, 2016 and 2024
     12.7. Asia Pacific Pulmonary Drugs Market Size (US$ Mn) Forecast, by Application, 2016–2024
     12.8. Asia Pacific Market Value Share Analysis, by Distribution Channel, 2016 and 2024
     12.9. Asia Pacific Pulmonary Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
     12.10. Asia Pacific Market Value Share Analysis, by Country, 2016 and 2024
     12.11. Asia Pacific Pulmonary Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2024
     12.12. Asia Pacific Market Attractiveness Analysis, by Drug Class
     12.13. Asia Pacific Market Attractiveness Analysis, by Application
     12.14. Asia Pacific Market Attractiveness Analysis, by Distribution Channel

13. Latin America Pulmonary Drugs Market Analysis
     13.1. Key Findings
     13.2. Latin America Pulmonary Drugs Market Size (US$ Mn) Forecast, 2016–2024
     13.3. Latin America Market Attractiveness Analysis, by Country
     13.4. Latin America Market Value Share Analysis, by Drug Class, 2016 and 2024
     13.5. Latin America Pulmonary Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
     13.6. Latin America Market Value Share Analysis, by Application, 2016 and 2024
     13.7. Latin America Pulmonary Drugs Market Size (US$ Mn) Forecast, by Application, 2016–2024
     13.8. Latin America Market Value Share Analysis, by Distribution Channel, 2016 and 2024
     13.9. Latin America Pulmonary Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
     13.10. Latin America Market Value Share Analysis, by Country, 2016 and 2024
     13.11. Latin America Pulmonary Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2024
     13.12. Latin America Market Attractiveness Analysis, by Drug Class
     13.13. Latin America Market Attractiveness Analysis, by Application
     13.14. Latin America Market Attractiveness Analysis, by Distribution Channel

14. Middle East & Africa (MEA) Pulmonary Drugs Market Analysis
     14.1. Key Findings
     14.2. MEA Pulmonary Drugs Market Size (US$ Mn) Forecast, 2016–2024
     14.3. MEA Market Attractiveness Analysis, by Country
     14.4. MEA Market Value Share Analysis, by Drug Class, 2016 and 2024
     14.5. MEA Pulmonary Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
     14.6. MEA Market Value Share Analysis, by Application, 2016 and 2024
     14.7. MEA Pulmonary Drugs Market Size (US$ Mn) Forecast, by Application, 2016–2024
     14.8. MEA Market Value Share Analysis, by Distribution Channel, 2016 and 2024
     14.9. MEA Pulmonary Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
     14.10. MEA Market Value Share Analysis, by Country, 2016 and 2024
     14.11. MEA Pulmonary Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2024
     14.12. MEA Market Attractiveness Analysis, by Drug Class
     14.13. MEA Market Attractiveness Analysis, by Application
     14.14. MEA Market Attractiveness Analysis, by Distribution Channel

15. Competition Landscape
     15.1. Global Pulmonary Drugs Market Share Analysis, By Company, (2015)
     15.2. Competition Matrix

16. Company Profiles
     16.1. AstraZeneca plc
                          16.1.1. Company Overview
             16.1.2. Business Overview
             16.1.3. Financial Overview
             16.1.4. SWOT Analysis
             16.1.5. Strategic Overview
     16.2. Bayer AG 
             16.2.1. Company Overview
             16.2.2. Business Overview
             16.2.3. Financial Overview
             16.2.4. SWOT Analysis
             16.2.5. Strategic Overview
     16.3. Teva Pharmaceutical Industries Ltd. 
             16.3.1. Company Overview
             16.3.2. Business Overview
             16.3.3. Financial Overview
             16.3.4. SWOT Analysis
             16.3.5. Strategic Overview
     16.4. Actelion Pharmaceuticals, Inc.
             16.4.1. Company Overview
             16.4.2. Business Overview
             16.4.3. Financial Overview
             16.4.4. SWOT Analysis
             16.4.5. Strategic Overview
     16.5. Boehringer Ingelheim GmbH
             16.5.1. Company Overview
             16.5.2. Business Overview
             16.5.3. Financial Overview
             16.5.4. SWOT Analysis
             16.5.5. Strategic Overview
     16.6. F. Hoffmann-La Roche Ltd.
             16.6.1. Company Overview
             16.6.2. Business Overview
             16.6.3. Financial Overview
             16.6.4. SWOT Analysis
             16.6.5. Strategic Overview
     16.7. Merck & Co., Inc.
             16.7.1. Company Overview
             16.7.2. Business Overview
             16.7.3. Financial Overview
             16.7.4. SWOT Analysis
             16.7.5. Strategic Overview
     16.8. Novartis AG 
             16.8.1. Company Overview
             16.8.2. Business Overview
             16.8.3. Financial Overview
             16.8.4. SWOT Analysis
             16.8.5. Strategic Overview
     16.9. GlaxoSmithKline plc
             16.9.1. Company Overview
             16.9.2. Business Overview
             16.9.3. Financial Overview
             16.9.4. SWOT Analysis
             16.9.5. Strategic Overview
     16.10. Sunovion Pharmaceuticals, Inc. 
             16.10.1. Company Overview
             16.10.2. Business Overview
             16.10.3. Financial Overview
             16.10.4. SWOT Analysis
             16.10.5. Strategic Overview

List of Figures

FIGURE 1 Global Pulmonary Drug Market Value Share Analysis, by Drug Class, 2016 and 2024
FIGURE 2 Global Inhaled Corticosteroids (ICS) Market Revenue, US$ Mn, 2014–2024
FIGURE 3 Global Long-Acting Beta2-Agonists (LABA) Market Revenue, US$ Mn, 2014–2024
FIGURE 4 Global Combination Drugs Market Revenue, US$ Mn,  2014–2024
FIGURE 5 Global Anticholinergics Market Revenue, US$ Mn, 2014–2024
FIGURE 6 Global Short-Acting Beta2-Agonists (SABA) Market Revenue, US$ Mn,  2014–2024
FIGURE 7 Global Antihistamines Market Revenue, US$ Mn,
FIGURE 8 Global Vasodilators Market Revenue, US$ Mn, 
FIGURE 9 Global Other Pulmonary Drugs Market Revenue, US$ Mn, 2014–2024
FIGURE 10 Pulmonary Drug Market Attractiveness Analysis, by Drug Class
FIGURE 11 Global Pulmonary Drug Market Value Share Analysis, by Applications, 2016 and 2024
FIGURE 12 Global Drugs Market Revenue, US$ Mn, 
FIGURE 13 Global Vaccines Market Revenue, US$ Mn,
FIGURE 14 Global Drugs Market Revenue, US$ Mn, 
FIGURE 15 Global Vaccines Market Revenue, US$ Mn,
FIGURE 16 Global Drugs Market Revenue, US$ Mn, 
FIGURE 17 Pulmonary Drug Market Attractiveness Analysis, by Applications
FIGURE 18 Global Pulmonary Drug Market Value Share Analysis, by Distribution Channel, 2016 and 2024
FIGURE 19 Global Drugs Market Revenue, US$ Mn, 
FIGURE 20 Global Vaccines Market Revenue, US$ Mn,
FIGURE 21 Global Drugs Market Revenue, US$ Mn, 
FIGURE 22 Global Vaccines Market Revenue, US$ Mn,
FIGURE 23 Global Pulmonary Drug Market Attractiveness Analysis, by Distribution Channel
FIGURE 24 Global Pulmonary Drug Market Value Share Analysis, by Region, 2016 and 2024
FIGURE 25 Pulmonary Drug Market Attractiveness Analysis, by Region
FIGURE 26 North America Pulmonary Drug Market Size (US$ Mn) Forecast, 2016–2024
FIGURE 27 North America Market Attractiveness Analysis, by Country
FIGURE 28 North America Market Value Share Analysis, by Drug Class, 2016 and 2024
FIGURE 29 North America Market Value Share Analysis, by Applications, 2016 and 2024
FIGURE 30 North America Market Value Share Analysis, by Distribution Channel, 2016 and 2024
FIGURE 31 North America Market Value Share Analysis, by Country, 2016 and 2024
FIGURE 32 North America Market Attractiveness Analysis, by Drug Class 
FIGURE 33 North America Market Attractiveness Analysis, by Applications
FIGURE 34 North America Market Attractiveness Analysis, by Distribution Channel
FIGURE 35 Europe Pulmonary Drug Market Size (US$ Mn) Forecast, 2016–2024
FIGURE 36 Europe Market Attractiveness Analysis, by Country
FIGURE 37 Europe Market Value Share Analysis, by Drug Class, 2016 and 2024
FIGURE 38 Europe Market Value Share Analysis, by Applications, 2016 and 2024
FIGURE 39 Europe Market Value Share Analysis, by Distribution Channel, 2016 and 2024
FIGURE 40 Europe Market Value Share Analysis, by Country, 2016 and 2024
FIGURE 41 Europe Market Attractiveness Analysis, by Drug Class
FIGURE 42 Europe Market Attractiveness Analysis, by Applications
FIGURE 43 Europe Market Attractiveness Analysis, by Distribution Channel
FIGURE 44 Asia Pacific Pulmonary Drug Market Size (US$ Mn) Forecast, 2014–2024
FIGURE 45 Asia Pacific Market Attractiveness Analysis, by Country
FIGURE 46 Asia Pacific Market Value Share Analysis, by Drug Class, 2016 and 2024
FIGURE 47 Asia Pacific Market Value Share Analysis, by Applications, 2016 and 2024
FIGURE 48 Asia Pacific Market Value Share Analysis, by Distribution Channel, 2016 and 2024
FIGURE 49 Asia Pacific Market Value Share Analysis, by Country, 2016 and 2024
FIGURE 50 Asia Pacific Market Attractiveness Analysis, by Drug Class
FIGURE 51 Asia Pacific Market Attractiveness Analysis, by Applications
FIGURE 52 Asia Pacific Market Attractiveness Analysis, by Distribution Channel
FIGURE 53 Latin America Pulmonary Drug Market Size (US$ Mn) Forecast, 2014–2024
FIGURE 54 Latin America Market Attractiveness Analysis, by Country
FIGURE 55 Latin America Market Value Share Analysis, by Drug Class, 2016 and 2024
FIGURE 56 Latin America Market Value Share Analysis, by Applications, 2016 and 2024
FIGURE 57 Latin America Market Value Share Analysis, by Distribution Channel, 2016 and 2024
FIGURE 58 Latin America Market Value Share Analysis, by Country, 2016 and 2024
FIGURE 59 Latin America Market Attractiveness Analysis, by Drug Class
FIGURE 60 Latin America Market Attractiveness Analysis, by Applications
FIGURE 61 Latin America Market Attractiveness Analysis, by Distribution Channel
FIGURE 62 Middle East & Africa Pulmonary Drug Market Size (US$ Mn) Forecast, 2014–2024
FIGURE 63 Middle East & Africa Market Attractiveness Analysis, by Country
FIGURE 64 Middle East & Africa Market Value Share Analysis, by Drug Class, 2016 and 2024
FIGURE 65 Middle East & Africa Market Value Share Analysis, by Applications, 2016 and 2024
FIGURE 66 Middle East & Africa Market Value Share Analysis, by Distribution Channel, 2016 and 2024
FIGURE 67 Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2024
FIGURE 68 Middle East & Africa Market Attractiveness Analysis, by Drug Class
FIGURE 69 Middle East & Africa Market Attractiveness Analysis, by Applications
FIGURE 70 Middle East & Africa Market Attractiveness Analysis, by Distribution Channel
FIGURE 71 Global Pulmonary Drug Market Share Analysis, by Company (2015)

List of Tables

TABLE 1 Global Pulmonary Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
TABLE 2 Global Pulmonary Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
TABLE 3 Global Pulmonary Drugs Market Size (US$ Mn) Forecast, 2014–2024
TABLE 4 Global Pulmonary Drugs Market Size (US$ Mn) Forecast, 2014–2024
TABLE 5 Global Pulmonary Drugs Market Size (US$ Mn) Forecast, 2014–2024
TABLE 6 Global Pulmonary Drug Market Size (US$ Mn) Forecast, by Region, 2016–2024
TABLE 7 North America Pulmonary Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
TABLE 8 North America Pulmonary Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
TABLE 9 North America Pulmonary Drug Market Size (US$ Mn) Forecast, by Applications, 2016–2024
TABLE 10 North America Pulmonary Drug Market Size (US$ Mn) Forecast, by Applications, 2016–2024
TABLE 11 North America Pulmonary Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 12 North America Pulmonary Drug Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 13 Europe Pulmonary Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
TABLE 14 Europe Pulmonary Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
TABLE 15 Europe Pulmonary Drug Market Size (US$ Mn) Forecast, by Applications, 2016–2024
TABLE 16 Europe Pulmonary Drug Market Size (US$ Mn) Forecast, by Applications, 2016–2024
TABLE 17 Europe Pulmonary Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 18 Europe Pulmonary Drug Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 19 Asia Pacific Pulmonary Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
TABLE 20 Asia Pacific Pulmonary Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
TABLE 21 Asia Pacific Pulmonary Drug Market Size (US$ Mn) Forecast, by Applications, 2016–2024
TABLE 22 Asia Pacific Pulmonary Drug Market Size (US$ Mn) Forecast, by Applications, 2016–2024
TABLE 23 Asia Pacific Pulmonary Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 24 Asia Pacific Pulmonary Drug Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 25 Latin America Pulmonary Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
TABLE 26 Latin America Pulmonary Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
TABLE 27 Latin America Pulmonary Drug Market Size (US$ Mn) Forecast, by Applications, 2016–2024
TABLE 28 Latin America Pulmonary Drug Market Size (US$ Mn) Forecast, by Applications, 2016–2024
TABLE 29 Latin America Pulmonary Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 30 Latin America Pulmonary Drug Market Size (US$ Mn) Forecast, by Country, 2014–2024
TABLE 31 Middle East & Africa Pulmonary Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
TABLE 32 Middle East & Africa Pulmonary Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
TABLE 33 Middle East & Africa Pulmonary Drug Market Size (US$ Mn) Forecast, by Applications, 2016–2024
TABLE 34 Middle East & Africa Pulmonary Drug Market Size (US$ Mn) Forecast, by Applications, 2016–2024
TABLE 35 Middle East & Africa Pulmonary Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 36 Middle East & Africa Pulmonary Drug Market Size (US$ Mn) Forecast, by Country, 2014–2024

Global Pulmonary Drugs Market: Snapshot

This report on pulmonary drugs studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered within the scope of the study. This section also provides the overall information and data analysis of the global pulmonary drugs market with respect to the leading market segments based on major products, key applications, distribution channels, and geographies.

Global Pulmonary Drugs Market: Segmentation

The global pulmonary drugs market has been studied based on major drug classes, application segments, major distribution channels, and regional as well as national markets. Based on drug classes, the global market has been categorized into eight major segments: Inhaled corticosteroids (ICS), long-acting beta2-agonists (LABA), antihistamines, vasodilators, short-acting beta2-agonists (SABA), anticholinergics, combination drugs, and others. Based on application, the global market has been categorized into five segments: Asthma & COPD, allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and others. Based on distribution channels, the global market has been categorized into four key segments: hospital pharmacies, retail pharmacies, drug stores, and e-commerce.

The market for these segments has been extensively analyzed based on their utility, effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn for the period from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all segments, considering 2015 as the base year.

Global Pulmonary Drugs Market: Scope

The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the global pulmonary drugs market and could influence the market in the near future. Market attractiveness analysis has been provided in all the sections of the report in order to explain the intensity of competition in the market across different products/applications/distribution channels/geographies. The competitive scenario among different market players is evaluated through market share analysis in the competition landscape section of the pulmonary drugs market report. The section also includes competition matrix that analyzes the competition among some of the top global players operating in the market. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global pulmonary drugs market.

Global Pulmonary Drugs Market: Geographical Outlook

Geographically, the pulmonary drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). Each regional market for pulmonary drugs market has been further categorized into major product, application, and end-user segments considered within the scope of the study. Key country (U.S., Japan, Germany, France, U.K., Australia, Canada, China, Brazil, Mexico, India, etc.) market revenues have also been provided in different regional sections within the report. Market revenue in terms of US$ Mn for the period from 2014 to 2024 along with CAGR % from 2016 to 2024 are provided for all the regions and nations considering 2015 as the base year.

Key Players Mentioned in the Report are:

The report also profiles key players operating in the pulmonary drugs market based on various attributes such as company details, SWOT analysis, strategic overview, financials, and business overview. Major players profiled in this report include AstraZeneca plc, Novartis AG, F. Hoffmann-La Roche Ltd, Bayer AG, GlaxoSmithKline plc, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Actelion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Sunovion Pharmaceuticals, Inc. and others

The global pulmonary drugs market has been segmented as follows:

Global Pulmonary Drugs Market Revenue, by Drug Class

  • Inhaled Corticosteroids (ICS)
  • Long-Acting Beta2-Agonists (LABA)
  • Antihistamines
  • Vasodilators
  • Short-Acting Beta2-Agonists (SABA)
  • Anticholinergics
  • Combination Drugs
  • Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)

Global Pulmonary Drugs Market Revenue, by Application

  • Asthma & COPD
  • Allergic Rhinitis
  • Pulmonary Arterial Hypertension
  • Cystic Fibrosis
  • Others

Global Pulmonary Drugs Market Revenue, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • E-commerce

Global Pulmonary Drugs Market Revenue, by Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa


 
 
Back To Top